The Indivior PLC - Ordinary Shares (INDV) share price is expected to increase by 72.04% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered INDV. Price targets range from $16 at the low end to $16 at the high end. The current analyst consensus for INDV is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedINDV 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Indivior PLC - Ordinary Shares to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on INDV. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of INDV.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
David Amsellem Piper Sandler | Overweight | $16 | Reiterates | Oct 25, 2024 |
Chase Knickerbocker Craig-Hallum | Buy | $16 | Maintains | Oct 11, 2024 |
David Amsellem Piper Sandler | Overweight | $15 | Reiterates | Oct 11, 2024 |
David Amsellem Piper Sandler | Overweight | $22 | Reiterates | Sep 13, 2024 |
David Amsellem Piper Sandler | Overweight | $22 | Initiates | Jul 23, 2024 |
Chase Knickerbocker Craig-Hallum | Buy | $24 | Maintains | Jul 10, 2024 |
Chase Knickerbocker Craig-Hallum | Buy | $37 | Initiates | Apr 3, 2024 |
When did it IPO
2014
Staff Count
1,000
Country
United States
Sector/Industry
Healthcare/Drug ManufacturersโSpecialty & Generic
CEO
Mr. Mark Crossley
Market Cap
$1.18B
In 2023, INDV generated $1.09B in revenue, which was a increase of 21.31% from the previous year. This can be seen as a signal that INDV's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Indivior PLC highlighted key findings on the effectiveness of SUBLOCADEยฎ for treating opioid use disorder, emphasizing improvements in abstinence and recovery outcomes.
Why It Matters - Indivior's update on SUBLOCADE's effectiveness strengthens its market position in opioid treatment, potentially boosting sales and investor confidence in its growth prospects.
Summary - Indivior PLC maintains its full-year outlook despite recent profit warnings. In Q3 results, it noted short-term challenges but reassured investors about long-term prospects amid competition.
Why It Matters - Indivior's maintained outlook amid recent profit warnings signals potential stability, but increased competition from Brixadi poses risks to market share and future earnings.
Summary - Indivior PLC shares rose 11% after reaffirming its full-year outlook. Q3 revenue increased 13% to $307M, with Sublocade sales up 14% to $191M despite competition.
Why It Matters - Indivior's strong revenue growth and reaffirmed outlook amid competition boost investor confidence, signaling resilience and potential for continued profitability in the opioid treatment market.
Summary - Indivior PLC (NASDAQ:INDV) will host its Q3 2024 earnings conference call on October 24, 2024, at 8:00 AM ET, featuring key executives and analysts.
Why It Matters - The Q3 2024 earnings call for Indivior PLC will provide insights into the company's financial health and strategic direction, impacting stock performance and investor sentiment.
Summary - Indivior PLC released its financial results for Q3 2024, ending September 30. Further details on performance were not provided in the excerpt.
Why It Matters - Indivior's financial results can impact stock performance, indicating growth or decline, influencing investor sentiment and potential investment decisions.
Summary - Indivior PLC reported Q3 earnings of $0.54 per share, exceeding the Zacks estimate of $0.39 and up from $0.34 per share year-over-year.
Why It Matters - Indivior's earnings beat estimates, indicating strong performance and growth, which could boost investor confidence and positively impact stock value.